Want to see TSE:OPTI full AI Analyst Report?
Top Page
Optimi Health
(OPTI)
Select Model
Select Model
Rating:44Neutral
Price Target:
C$6.50
▼(-4.83% Downside)
Action:Reiterated
Date:08/25/26
The score is held down primarily by weak financial performance—persistent losses, negative margins, and significant cash burn—along with a loss-making valuation profile (negative P/E, no dividend). Technical indicators are neutral and do not show strong momentum, while the new equity line modestly improves funding flexibility but brings potential dilution risk.
Positive Factors
Diversified Mushroom Platform
The company participates across cultivation, processing, and supply rather than relying on one product format. This platform can support functional mushroom, research, and legally permitted psychedelic applications as regulated markets and customer needs develop.
Negative Factors
Persistent Unprofitability
Deeply negative gross and operating margins indicate that current production and sales do not yet cover the cost of generating revenue. Persistent losses reduce internally generated capital and make the path to self-sustaining growth dependent on operational improvement.
Read all positive and negative factors
Positive Factors
Negative Factors
Diversified Mushroom Platform
The company participates across cultivation, processing, and supply rather than relying on one product format. This platform can support functional mushroom, research, and legally permitted psychedelic applications as regulated markets and customer needs develop.
Read all positive factors
Optimi Health (OPTI) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$37.96M
Dividend YieldN/A
Average Volume (3M)4.57K
Price to Earnings (P/E)―
Beta (1Y)0.55
Revenue GrowthN/A
EPS GrowthN/A
CountryCA
Employees9
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-1.95
Shares Outstanding5,725,867
10 Day Avg. Volume2,270
30 Day Avg. Volume4,574
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)5.70
Price to Sales (P/S)87.81
P/FCF Ratio-13.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Optimi Health Business Overview & Revenue Model
Company Description
Optimi Health Corp. focuses on developing an integrated brand of functional mushrooms specifically for the Canadian health and wellness food markets. The company manages the entire process from the cultivation and extraction to the processing and ...
How the Company Makes Money
Optimi Health makes money primarily by selling mushroom-related products and services across a few core channels: (1) Product sales from cultivation and processing: Revenue is generated through the production and sale of functional mushrooms and, ...
Optimi Health Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
34
Negative
Cash Flow
16
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 175.67K | 426.30K | 389.85K | 181.09K | 80.72K | 0.00 |
| Gross Profit | -3.68M | -2.07M | 270.91K | -157.04K | 53.92K | -47.12K |
| EBITDA | -4.93M | -2.23M | -4.74M | -4.42M | -7.03M | -5.95M |
| Net Income | -6.90M | -3.71M | -6.04M | -5.19M | -7.38M | -6.04M |
Balance Sheet | ||||||
| Total Assets | 25.86M | 15.21M | 14.55M | 16.49M | 16.82M | 23.46M |
| Cash, Cash Equivalents and Short-Term Investments | 13.07M | 1.15M | 103.66K | 1.34M | 1.89M | 12.43M |
| Total Debt | 5.14M | 6.68M | 2.75M | 1.71M | 157.58K | 250.84K |
| Total Liabilities | 8.22M | 8.64M | 4.98M | 3.28M | 797.66K | 2.40M |
| Stockholders Equity | 17.64M | 6.57M | 9.58M | 13.21M | 16.02M | 21.07M |
Cash Flow | ||||||
| Free Cash Flow | -5.31M | -2.72M | -4.43M | -4.41M | -11.73M | -10.96M |
| Operating Cash Flow | -5.20M | -2.63M | -4.28M | -3.60M | -4.58M | -6.02M |
| Investing Cash Flow | -109.68K | -88.38K | -154.02K | -706.02K | -3.15M | -9.19M |
| Financing Cash Flow | 18.29M | 3.76M | 3.19M | 3.76M | 1.19M | 19.18M |
Optimi Health Technical Analysis
Negative
6.83
Price Trends
6.66
Negative
7.60
Negative
8.56
Negative
Market Momentum
-0.01
Positive
47.46
Neutral
20.84
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:OPTI, the sentiment is Negative. The current price of 6.83 is above the 20-day moving average (MA) of 6.70, above the 50-day MA of 6.66, and below the 200-day MA of 8.56, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 47.46 is Neutral, neither overbought nor oversold. The STOCH value of 20.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:OPTI.
Optimi Health Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | C$32.44M | -19.51 | -4.00% | ― | 16.66% | -1007.41% | |
53 Neutral | C$32.04M | -6.47 | -13.79% | ― | -6.74% | 43.54% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | C$16.37M | -5.04 | 46.54% | ― | 4.30% | 38.28% | |
46 Neutral | C$17.47M | -4.01 | -108.44% | ― | -0.23% | -142.54% | |
44 Neutral | C$37.96M | -3.39 | -84.23% | ― | ― | ― | |
41 Neutral | C$11.21M | -3.21 | 28.59% | ― | 0.90% | 57.73% |
* Healthcare Sector Average
TSE:OPTI
Optimi Health
6.63
-1.02
-13.32%
TSE:DOSE
Rapid Dose Therapeutics Corp
0.12
-0.06
-33.33%
TSE:LABS
MediPharm Labs
0.08
<0.01
7.14%
TSE:PCLO
PharmaCielo
0.06
0.02
33.33%
TSE:ROMJ
Rubicon Organics
0.48
-0.09
-15.79%
TSE:AVCN
Avicanna
0.13
-0.14
-51.85%
Optimi Health Corporate Events
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Optimi Health Sets Up US$100 Million Equity Line for Psychedelic Drug Expansion
Positive
Aug 14, 2026
Optimi Health Corp. has established a discretionary equity line of credit of up to US$100 million with Seven Knots, LLC, allowing the company to sell common shares at its own discretion, subject to pricing formulas, per-draw limits, ownership caps...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.